Core Insights - Polarean Imaging has signed an exclusive distribution agreement with DK Healthcare for its Xenon MRI platform in South Korea, marking its second international distribution partnership and enhancing its commercial presence in the Asia-Pacific region [1][2]. Company Overview - Polarean Imaging is a leader in functional MRI technology for lung imaging, focusing on the direct visualization of lung function and addressing the unmet medical needs of over 500 million patients with chronic respiratory diseases globally [5]. - The company has developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW™, which is FDA-approved in the United States [5]. Partnership Details - The partnership with DK Healthcare aims to facilitate the regulatory clearances necessary for the commercial launch of the Xenon MRI platform in South Korea, a market known for its advanced medical imaging capabilities [2][4]. - DK Healthcare, a prominent provider of diagnostic radiology systems in Korea, has a strong reputation for delivering innovative imaging solutions and support [3][6]. Market Potential - South Korea's focus on early detection and precision medicine positions it as an ideal growth market for Polarean's technology, which enhances lung function assessment and aims to improve outcomes for patients with conditions such as lung cancer and COPD [4].